Center for Clinical Management Research, Department of Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor.
JAMA Netw Open. 2024 Jul 1;7(7):e2419624. doi: 10.1001/jamanetworkopen.2024.19624.
Addressing poor uptake of low-dose computed tomography lung cancer screening (LCS) is critical, especially for those having the most to gain-high-benefit persons with high lung cancer risk and life expectancy more than 10 years.
To assess the association between LCS uptake and implementing a prediction-augmented shared decision-making (SDM) tool, which enables clinicians to identify persons predicted to be at high benefit and encourage LCS more strongly for these persons.
DESIGN, SETTING, AND PARTICIPANTS: Quality improvement interrupted time series study at 6 Veterans Affairs sites that used a standard set of clinical reminders to prompt primary care clinicians and screening coordinators to engage in SDM for LCS-eligible persons. Participants were persons without a history of LCS who met LCS eligibility criteria at the time (aged 55-80 years, smoked ≥30 pack-years, and current smoking or quit <15 years ago) and were not documented to be an inappropriate candidate for LCS by a clinician during October 2017 through September 2019. Data were analyzed from September to November 2023.
Decision support tool augmented by a prediction model that helps clinicians personalize SDM for LCS, tailoring the strength of screening encouragement according to predicted benefit.
LCS uptake.
In a cohort of 9904 individuals, the median (IQR) age was 64 (57-69) years; 9277 (94%) were male, 1537 (16%) were Black, 8159 (82%) were White, 5153 (52%) were predicted to be at intermediate (preference-sensitive) benefit and 4751 (48%) at high benefit, and 1084 (11%) received screening during the study period. Following implementation of the tool, higher rates of LCS uptake were observed overall along with an increase in benefit-based LCS uptake (higher screening uptake among persons anticipated to be at high benefit compared with those at intermediate benefit; primary analysis). Mean (SD) predicted probability of getting screened for a high-benefit person was 24.8% (15.5%) vs 15.8% (11.8%) for a person at intermediate benefit (mean absolute difference 9.0 percentage points; 95% CI, 1.6%-16.5%).
Implementing a robust approach to personalized LCS, which integrates SDM, and a decision support tool augmented by a prediction model, are associated with improved uptake of LCS and may be particularly important for those most likely to benefit. These findings are timely given the ongoing poor rates of LCS uptake.
解决低剂量计算机断层扫描肺癌筛查(LCS)接受度低的问题至关重要,尤其是对于那些受益最大的人群,即肺癌风险高、预期寿命超过 10 年的高获益人群。
评估 LCS 接受度与实施预测增强的共享决策(SDM)工具之间的关联,该工具使临床医生能够识别出预计获益高的人群,并为这些人群更强烈地推荐 LCS。
设计、地点和参与者:这是一项在 6 个退伍军人事务地点进行的质量改进中断时间序列研究,该研究使用了一套标准的临床提醒,以促使初级保健临床医生和筛查协调员对符合 LCS 条件的人群进行 LCS 的 SDM。参与者是那些没有接受过 LCS 且在 2017 年 10 月至 2019 年 9 月期间符合 LCS 条件(年龄 55-80 岁,吸烟≥30 包年,目前吸烟或戒烟<15 年),且临床医生未记录为不适合进行 LCS 的人群。数据于 2023 年 9 月至 11 月进行分析。
决策支持工具辅以预测模型,帮助临床医生针对 LCS 进行个性化 SDM,根据预测的获益程度调整筛查鼓励的力度。
LCS 接受度。
在 9904 名个体的队列中,中位(IQR)年龄为 64(57-69)岁;9277 名(94%)为男性,1537 名(16%)为黑人,8159 名(82%)为白人,5153 名(52%)预计处于中(偏好敏感)获益,4751 名(48%)处于高获益,1084 名(11%)在研究期间接受了筛查。在该工具实施后,总体上 LCS 接受度更高,并且基于获益的 LCS 接受度也有所增加(预计高获益人群的筛查接受度高于中获益人群;主要分析)。高获益人群接受筛查的平均(SD)预测概率为 24.8%(15.5%),中获益人群为 15.8%(11.8%)(平均绝对差异 9.0 个百分点;95%CI,1.6%-16.5%)。
实施一种强大的个体化 LCS 方法,整合 SDM,并结合预测模型增强的决策支持工具,与 LCS 接受度的提高相关,可能对那些最有可能受益的人群尤其重要。鉴于目前 LCS 接受度较低,这些发现非常及时。